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Growing prevalence of atrial fibrillation (AF) in the ageing population, and its associated life-
changing health and resource implications, have led to a need to improve its early detection. 
Primary care is an ideal place to screen for AF, however this is limited by shortages in general 
practitioner (GP) resources. Recent increases in the number of clinical pharmacists within 
primary care, makes them ideally placed to conduct AF screening. This study aimed to 
determine the feasibility of GP practice-based clinical pharmacists to screen the over 65s for 
AF, using digital technology and pulse palpation during the influenza vaccination season.  
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Methods and Findings 
Screening was conducted over two influenza vaccination seasons, 2017-2018 and 2018-2019 
in four GP practices in Kent, UK. Pharmacists were trained by a cardiologist to pulse palpate, 
record and interpret a single-lead ECG (SLECG).  Eligible persons aged ≥65 years, attending an 
influenza vaccination clinic were offered a free heart rhythm check.  
604 participants were screened (median age 73 years, 42.7% male). Total prevalence of AF 
was 4.3%. All participants with AF qualified for anticoagulation and were more likely to be 
male (57.7%); older; have an increased BMI and have a CHA2DS2-VASc (Congestive heart 
failure, Hypertension, Age ≥ 75, Diabetes, previous Stroke, Age 65-74 years, Sex category) 
score ≥ 3. The sensitivity and specificity of clinical pharmacists diagnosing AF using pulse 
palpation was 76.9% [95% CI: 56.4-91.0] and 92.2% [89.7-94.3], respectively. This rose to 
88.5% (69.9-97.6) and 97.2% [95.5-98.4] with a SLECG. At follow-up, four participants (0.7%) 
were diagnosed with new AF and 3 (0.5%) were initiated on anticoagulation. Screening with 
SLECG also helped identify new non-AF cardiovascular diagnoses, such as left ventricular 
hypertrophy, in 28 participants (4.6%). The screening strategy was cost-effective in 71.8% and 
64.3% of the estimates for SLECG or pulse palpation, respectively. Feedback from participants 
(422/604) was generally positive. Key limitations of the study were that the intervention did 
not reach individuals who did not attend the practice for an influenza vaccination and there 






This study demonstrates that AF screening performed by GP practice-based pharmacists was 
feasible, economically viable and positively endorsed by participants. Furthermore, diagnosis 
of AF by the clinical pharmacist using a SLECG was more sensitive and more specific than the 
use of pulse palpation alone. Future research should explore the key barriers preventing the 
adoption of national screening programmes. 
 
Author Summary 
Why was this study done? 
➢ Atrial fibrillation (AF), which is often symptomless, is associated with an increased risk 
of developing stroke or heart failure.  The prevalence of AF increases with age. 
Integration of screening programmes alongside existing healthcare services and 
infrastructure, utilising trained healthcare professionals (HCPs) must be sustainable. 
 
➢  Screening for AF at influenza vaccination clinics using clinical pharmacists may be 
cost-effective and target a relevant, at-risk proportion of the population (e.g. ≥ 65 
years, with multiple conditions). 
 
What did the researchers do and find? 
➢ Using a single time-point screening strategy which selectively targeted 604 people ≥65 
years, attending influenza vaccination clinics at participating General Practitioner 
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practices, we showed that appropriately trained clinical pharmacists could screen and 
detect AF. 
 
➢ A participant experience questionnaire showed, generally, that participants were 
highly satisfied with their consultation and thought AF screening was important. 
 
➢ We found that screening for AF during the influenza vaccination season, using clinical 
pharmacists and automated digital technology was more reliable and cost-effective 
than pulse-palpation alone. 
 
What do these findings mean? 
➢ This work demonstrates a feasible approach to annual AF screening in primary care by 
clinical pharmacists using digital technology, that could be readily adopted by general 
practices, delivering annual influenza vaccinations to the over 65’s and adapted to 
involve other HCPs.  
 
➢ Further studies are needed to investigate how to broaden AF screening to those at-
risk who do not participate in the influenza vaccination and to explore the key barriers 







Routine screening for atrial fibrillation (AF) is currently not endorsed by the UK National 
Screening Committee [1]. The growing prevalence of AF [2,3] and its associated life-changing 
health implications [4,5], combined with the impact of AF on national health resources [6] 
that can occur as a result of the disease not being detected early, has led to a growing medical 
consensus, backed by public health policy, to improve the early detection and treatment of 
AF [7-9]. 
The prevalence and severity of AF increases with age [10] and the older-aged population are 
most at risk of suffering an AF-related stroke and/or heart failure [4,5]. Furthermore, the risk 
of the disease has been shown to be exacerbated when associated with other co- or multi-
morbidities, such as hypertension and heart failure [5,11-14]. For persons aged 55 years or 
older, the lifetime risk of developing AF increases from one in five to one in three in the 
presence of one or more morbidities [11]. The proportion of over 65s suffering from two or 
more chronic conditions is 54%, increasing to 69% for those over the age of 85 [15]. Thus the 
older, ageing population remains key to any future national screening plans, as highlighted by 
the European Society of Cardiology (ESC) guidelines [8]. When, where and how this 
population is targeted, remains a key consideration to any future screening initiatives, in 
order to maximise socio-economic outcomes.  
Primary care is considered to be central to improving the early detection of AF, as this is where 
the majority of the populations’ health is routinely managed. In England, general practitioner 
(GP) surgeries provide over 300 million patient consultations a year [16] making this location 
ideal for health screening [17-21]. The chronic shortage of doctors and nurses in the UK [22], 
and elsewhere, impacts heavily on patient access to primary care [23], despite efforts to retain 
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and increase GP numbers [24]. To address this issue, NHS England have pledged to fund an 
additional 20,000 health care professionals (HCPs) by 2023/24, to support GPs [25], with 
initial funding targeted to social prescribers and pharmacists. This builds on previous NHS 
investment into the ‘Clinical Pharmacists in General Practice’ pilot scheme, which, since 2015, 
has recruited over 1000 full time clinical pharmacists [26]. As such, health care interventions 
such as AF screening are likely to be delivered by another HCP, other than a GP. Clinical 
pharmacists are well placed to apply their in-depth knowledge of medicines, toxicology, 
pharmacokinetics and therapeutics to deliver patient-centred care that promotes health, 
well-being and disease prevention, in all patient care settings [27,28]. The development of 
newer and better screening methods for AF are also being shown to improve the detection 
of AF and are helping to overcome some of the limitations and barriers experienced using 
older more conventional methods [29,30].  
In this ‘Pharmacists Detecting Atrial Fibrillation’ (PDAF) study, we aimed to determine the 
feasibility of general practice-based clinical pharmacists screening the over 65s for AF, using 
digital technology and a single time-point screening strategy combined with another annual 
healthcare intervention, the influenza vaccination. We evaluated the use of a single-lead 
electrocardiogram (SLECG) device compared with pulse palpation alone, as the latter is a 
current recommendation for AF detection [31] and the economic impact of both methods 
particularly in relation to false-discovery rates. Finally, we sought feedback from the 
participants about the service that was provided. A preliminary account of some of these data 






This study is reported as per the Standards for Reporting Diagnostic accuracy studies (STARD) 
checklist (S1 STARD Checklist). 
 
Study Design 
A single time-point screening strategy was used to detect atrial fibrillation (AF), in patients 
aged 65 years or over, attending the annual influenza vaccination at their GP practice, using 
clinical pharmacists to conduct the screening. Screening was conducted over two influenza 
vaccination seasons, from the 28th October 2017 to the 22nd February 2018 and then from the 
2nd October to the 14th December 2018.  The study protocol design was described in a 
previous publication [33]. In brief, 5 clinical pharmacists were recruited from Kent Community 
NHS Foundation Trust, another pharmacist was already embedded in a participating practice 
and another was provided by the Medway School of Pharmacy, University of Greenwich and 
Kent. All pharmacists received training before and during the study to implement the 
screening protocol. Four GP practices across the NHS Canterbury and Coastal Clinical 
Commissioning Group participated in the study. Patients aged 65 or over attending an 
influenza clinic at a participating practice, were eligible to have the rate and rhythm of their 
heart assessed, using pulse palpation and a SLECG device (AliveCor Kardia Mobile Device – 
(KMD)). Exclusions from screening, included anyone with a pacemaker, a severe coexisting 
medical condition (e.g. cancer with <1 month of life expectancy) or those who were not able 
to provide informed consent at time of screening due to the lack of mental capacity. Patients 
with pre-existing AF were not excluded as it was assumed that most participants with AF 
would self-exclude, whilst those that didn’t would act as positive test controls. Pharmacists 
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were unaware of pre-existing AF diagnoses in participants, prior to screening. Participants 
could be screened at the clinic or could opt for a pre-booked appointment. Screening was 
advertised via posters, leaflets, text messages, staff, clinical pharmacists or a member of the 
study team. Participants were recruited using a consecutive sampling approach, meaning that 
any participants attending influenza vaccination clinics at participating practices, during the 
time periods, October 2017 to February 2018 and October 2018 – February 2019, who fulfilled 
the study inclusion criteria (see above) were invited to participate. All data with an exception 
of enhanced participant demographics were collected prospectively. 
 
Screening Procedure 
All eligible participants provided signed informed consent before entering the study. 
Consenting participants were assigned a de-identifying patient ID code, which was then used 
on all study documentation and recorded ECGs. Participants were asked to complete a basic 
demographics form (e.g. age, sex, ethnicity, height, weight, current smoking and drinking 
habits) prior to screening. Screening then followed the process outlined in Fig 1. The radial 
pulse of the participant was measured for 60 seconds (s), and this was then followed by a 
SLECG, recorded for 30 s. Only one ECG was recorded unless the ECG was of poor quality, then 
a second was recorded. The data of the last ECG recorded for each participant were used for 
subsequent analysis The ECG was assessed and interpreted by the clinical pharmacist. Their 
assessment of the ECG was explained to the participant and noted, along with the quality of 
the ECG recording. The clinical pharmacists were not blinded from knowing the provisional 
diagnosis of the KMD algorithm. All ECGs were emailed to the study cardiologist via the 
NHS.net email system for over-reading. The clinical pharmacist provided the participant with 
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a provisional diagnosis letter which was either ‘normal’, ‘possible AF’, ‘unclassified’ (not sinus 
rhythm or AF) or ‘unreadable’ and advised of the next steps. All ECGs were uploaded to 
participants’ electronic medical record and copies of the consent form and provisional 
diagnosis letter retained in the study file. The cardiologist’s interpretation of the ECG and 
recommendations for intervention were returned within 72 hours. The cardiologist was not 
blinded from knowing the provisional diagnoses by KMD algorithm or pharmacists and 
provided pharmacists with regular feedback once each provisional diagnosis was confirmed 
or rejected. All patient interventions, including confirmatory 12-lead ECGs (12LECG), were 
organised by the GP practice in accordance with their normal practice procedures. All 
participants given either an AF or unclassified/unreadable diagnosis and a recommendation 
for further intervention by the cardiologist were followed-up by the study team to ensure 
participants, had been offered appropriate treatment from their GP practice. The study team 
also collated enhanced demographics (e.g. medical history) from all patients with either an 
AF or unclassified/unreadable diagnosis and a random selection (n = 100)* of participants who 
had normal sinus rhythm (SR) at time of screening, for comparison. This sample of participants 
was selected using the random-cases function of SPSS (v25) in the presence of two 
researchers. *N.B. 7/100 participants were excluded from this selection as their medical 




Fig 1: Pharmacists detecting atrial fibrillation study intervention flow chart.  
Abbreviations: AF – atrial fibrillation; ECG – electrocardiogram; GP – general practitioner; HR 




Participant Experience Questionnaire 
At the end of the screening appointment all participants were asked to complete a short, 
anonymous, patient experience questionnaire consisting of 13 closed and 4 open questions 
(S1 Appendix) and were offered the opportunity to take part in future focus groups (reported 
elsewhere). Completed questionnaires were handed over to the receptionist or posted back 
to the research team using pre-paid envelopes.  
 
Quantitative Data Analysis 
Apart from the subgroup analysis pertaining to enhanced demographic data of selected 
participants with suspected ‘normal’ diagnoses, all data analyses were conducted as pre-
specified in the study protocol [33]. Continuous variables were reported as a median 
[interquartile range]. Categorical variables, including responses to closed questions of the 
participant experience questionnaire, were expressed as numbers and percentages (%). The 
demographics of individuals with and without AF were compared using a Mann Whitney U 
test for continuous variables and a Pearson Chi-square or Fisher’s exact test for categorical 
variables. Any missing data points were omitted from final analysis, without data imputation. 
For all statistical comparisons, p values of < 0.05 were considered significant.  
 
The level of inter-rater agreement between pulse palpation, pharmacist, device and 
cardiologist interpretation of the SLECG was calculated using Cohen’s Kappa statistic. 
Diagnostic accuracy parameters, including the sensitivity, specificity, % agreement with the 
cardiologist (positive predictive value; PPV) and the false discovery rate (FDR), for each index 
test were derived from 2x2 contingency tables using cardiologist’s interpretation of SLECG as 
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a reference test. The sensitivity and specificity of the test were defined as its ability to 
correctly identify those participants with AF (true positives/true positives and false negatives) 
and without AF (true negatives/true negatives and false positives), respectively [34]. The 
overall diagnostic accuracy (correct classification rate) combined these two parameters as an 
assessment of the test’s ability to detect both the proportions of true positives and true 
negatives (true positive and true negatives / total number of participants) [35]. The PPV and 
FDR were defined as probabilities that the test will identify those with positive diagnoses 
either correctly (PPV = number of participants who both tested positive and were true 
positives / total number who tested positive) or incorrectly (FDR = number of participants 
who both tested positive and were true negatives / total number who tested positive), 
respectively [34,36]. 
The diagnostic accuracy of pulse palpation, clinical pharmacist’s interpretation and the 
device’s algorithm (index tests) was compared with the cardiologist’s interpretation 
(reference standard) using a Cochran’s Q test followed by post-hoc McNemar’s Chi-square 
tests and a Bonferroni correction for multiple comparisons. Diagnostic accuracy parameters 
were expressed as a mean [95% confidence intervals (CI)].  
 
Prevalence of new AF diagnoses were determined from the number of confirmed AF-positive 
12LECGs divided by the total number screened with accompanying [95% CI]. False-positive 
results of each index test were expressed as the number of incorrect AF diagnoses compared 
to the cardiologist’s interpretation, divided by the total number screened [95% CI]. All 




Responses to open-ended questions of participant experience questionnaires were imported 
into NVivo (V.12) and analysed using content analysis [37], a systematic approach commonly 
applied to the analysis of verbatim questionnaire data [38]. This included coding the words 
and frequencies extracted from the questionnaires to identify the frequency of their 
occurrence and to group them into key themes. The themes were considered alongside 
responses to closed questions. 
 
Patient and Public Involvement 
The AF screening protocol and all patient related information and documents were presented 
to and scrutinised by the Medway School of Pharmacy, Public Involvement in Pharmacy 
Studies (PIPS) group prior to submission for ethics approval. Members were also involved in 
mock training sessions with the clinical pharmacists. The PIPS group is comprised of interested 
members of the public. No members of the PIPS group participated in the screening. 
 
The results of the study have been disseminated to participants via various forums including 
GP practice newsletters, press and media releases (BBC South East, KMTV and BBC Radio 
Kent) and social media.  
 
Ethics 
The study was approved by the London-Riverside Research Ethics committee (17/LO/1650) 
and NHS Health Research Authority. IRAS Project ID: 232663. The study was conducted in 
accordance with the Medical Research Council’s framework for complex interventions [39] 
and the recommendation for physicians involved in research on human subjects adopted by 






A total of 604 participants across four GP practices in Kent, underwent a heart rhythm check 
with a clinical pharmacist. Median age [interquartile range] of the participants was 73 [69, 78] 
years and 42.7% of participants were male. The majority of participants (96.9%) reported 
themselves to be White British and had a median body mass index (BMI) of 26.1 [23.5; 29.3], 
Table 1. Nearly 85% of participants only had one SLECG recording (512/604), although two or 
more ECGs were performed in 15.2% of participants (92/604) where the first recording was 
of poor quality. 
 
Table 1: A summary of participant demographic characteristics (n = 604). Continuous 
variables are expressed as a median [interquartile range]. Categorical variables are expressed 
as a number of participants (% total of the group). *White European, Flemish, Italian, Scottish 
and South African (n = 1 each), and White Non-specified or Other (n = 2). **Kazakh, American, 
Australian, Hungarian and Norwegian (n = 1 each). 
 
Age, years 73 [69; 78] 
Male 258 (42.7%) 
White British 585 (96.9%) 
White Irish 3 (0.5%) 
White American 2 (0.3%) 
White Dutch 2 (0.3%) 
White Other* 7 (1.2%) 
Other** 5 (0.8%) 
Current alcohol drinker  380 (62.9%) 
Alcohol, units/week  6 [2; 14] (n=372) 
Current smoker 54 (8.9%) 
Height, cm  167.0 [160.0; 174.0] (n=596) 
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Weight, kg 73.0 [64.0; 83.0] (n=588) 
BMI, kg/m2 26.1 [23.5; 29.3] (n=585) 
Heart rate device, bpm 72 [65; 81] 
 
Abbreviations: BMI – body mass index, bpm – beats per minute (heart rate). 
 
Screening for AF: Measurement Comparison 
Cardiologist 
The cardiologist was able to interpret 99% of the SLECGs recorded, with only 1% (6/604) of the 
SLECG recorded, deemed uninterpretable. From 598/604 SLECGs, the cardiologist diagnosed 
503 (83.3%) as normal SR, 26 (4.3%) as possible AF and 69 (11.4%) as either having 
unidentifiable or absent P waves or some other non-AF cardiac abnormality, such as bundle 




Fig 2: Screening for AF, measurement comparison. A breakdown of diagnoses derived from 
pulse palpation, KMD algorithm and pharmacist interpretation of the SLECG compared to the 
cardiologist’s interpretation of the SLECG. All data are expressed as the number of cases in 
each diagnostic category (% diagnostic agreement with cardiologist diagnoses). *  represents 
p = 0.001 for differences derived from 2 x 2 contingency tables for AF positive and AF negative 
diagnoses between KMD and pulse palpation and between pharmacist interpretation and 




SLECG interpretation by the KMD algorithm 
The KMD algorithm reported 484 (80%) cases as normal SR, 39 (6.5%) cases of possible AF, 75 
(12.4%) as unclassified and 6 (1.0%) of the ECGs as unreadable. Diagnostic agreement of the 
algorithm’s interpretation of the SLECG, compared to the cardiologist’s interpretation is 
illustrated in Fig 2 whilst sensitivity, specificity and accuracy of diagnosing AF from a SLECG is 
shown in Table 2. The KMD had a false positive rate of 2.6% and a false-discovery rate of 
38.5%. 
 
Table 2: A summary of diagnostic accuracy. Interpretation of SLECG by the KMD algorithm, 
pharmacist interpretation and pulse palpation when compared to the cardiologist 
interpretation (expressed as a mean [95% CI]).  
 






Discovery Rate  
Cohen’s Kappa 
KMD algorithm 
92.3 97.4 97.2 38.5 0.72 
[74.9 - 99.1] [95.8 - 98.5] [95.5 - 98.4] [23.4 - 55.4] [0.60 - 0.85] 
Pharmacist 
interpretation 
88.5 97.2 96.9 41.0 0.69 
[69.9 - 97.6] [95.5 - 98.4] [95.1 - 98.1] [25.6 - 57.9] [0.56 - 0.82] 
Pulse palpation 
76.9 92.2 91.6 69.2 0.40 
[56.4 - 91.0] [89.7 - 94.3] [89.1 - 93.7] [56.6 - 80.1] [0.27-0.53] 















































SLECG interpretation by the clinical pharmacists 
From the SLECG, clinical pharmacists were asked to record their own interpretation of the 
SLECG [normal SR, possible AF, unclassified or unreadable]. The clinical pharmacists reported 
487 (80.6%) cases as normal SR, 39 (6.5%) cases of possible AF, (35 of these matched with the 
KMD algorithm), 71 (11.8%) unclassified and 7 (1.2%) of the ECGs as unreadable. Diagnostic 
agreement of the clinical pharmacist’s interpretation of the SLECG, compared to the 
cardiologist’s interpretation is illustrated in Fig 2, whilst sensitivity, specificity and accuracy of 
diagnosing AF from a SLECG by the clinical pharmacists is shown in Table 2. The clinical 
pharmacists’ interpretation of the SLECG had false positive rate of 2.8% and a false discovery 
rate of 41.0%. The quality of the SLECG recorded for 604 participants was deemed as either 
Excellent (60%); Acceptable (33%); Poor (5%); or Unreadable (2%) by the pharmacists. 
 
Pulse palpation by the Clinical Pharmacist 
Heart rate and rhythm interpretation of the pulse was obtained by the pharmacist for 603 
participants, with pulse interpretation data missing for 1 case, where pulse could not be 
palpated. Average heart rate was determined by the pharmacist to be 70 beats per minute 
(bpm) [62; 78], compared to 72 bpm [65; 81], n = 604, obtained using the KMD.  
Using pulse palpation alone, pharmacists reported 526 (87.1%) cases as normal SR, 65 (10.8%) 
cases of possible AF, 12 (2.0%) as unclassified and one (0.2%) as unreadable (i.e. impalpable). 
Diagnostic agreement of pulse palpation with the cardiologist’s interpretation of the SLECG is 
illustrated in Fig 2, whilst sensitivity, specificity and accuracy of diagnosing AF using pulse 
palpation are shown in Table 2. For pulse interpretation, false positive and false discovery 
17 
 
rates were high (7.8% and 69.2% respectively). False-positive AF diagnoses occurred as a 
consequence of multiple atrial or ventricular ectopic beats (n = 23), mild sinus tachycardia (n 
= 2) or bradycardia (n = 1) where indicated by the cardiologist’s interpretation of the SLECG. 
 
AF Prevalence 
The total prevalence of ‘known’ and ‘new’ AF ascertained by the cardiologist’s interpretation 
of SLECG recordings was 4.3% (26/604). Of these 26 participants, 18/26 (3.0%) had a known 
medical history of AF, were in AF when screened and no further action was taken. A total of 
8 (1.3%) possible-AF participants were referred for a 12LECG. Three (0.5%) of these referred 
participants remained in AF at time of the 12LECG. In total, 4/604 (0.7%) participants were 
diagnosed with ‘new’ AF as a result of screening after a 12LECG confirmation (3 with initially 
suspected ‘possible AF’ and 1 with an ‘unclassified’ diagnosis). Interestingly, of the 18 ‘known’ 
AF patients, all of whom were receiving OAC treatment, only seven reported at the time of 
screening, that they suffered from AF and were receiving anticoagulation therapy and 3 
participants were unsure about their diagnosis or treatment warranting a confirmation in 
their medical records. All 26 ‘known’ and ‘actionable’ AF participants were eligible for OACs 
in accordance with ESC guidelines [8]. Of the 26 participants eligible for OAC therapy, 20 
(76.9%) were on OAC therapy, at the end of the study (18 with ‘known’ and 2 with ‘new AF’). 
An additional participant with a provisional ‘unclassified’ diagnosis who was diagnosed with 





Demographics of ‘new’ and ‘known’ AF participants 
Participants with AF were more likely to be male; were significantly older (p < 0.0001); had a 
significantly higher BMI (p = 0.01); and a CHA2DS2-VASc score ≥ 3 (p = 0.002), compared to a 
random sample (n = 93) of participants, that were deemed normal SR, at time of screening 
(Table 3). Extended demographics of participants identified with AF showed that they were 
significantly more likely to suffer from hypertension, renal disease, diabetes mellitus and 
heart failure (Table 3). Average number of comorbidities per participant from within the AF 
cohort was 2.0 [1.0; 3.0] (n = 26), compared to 1.0 [0.0; 2.0] for the non-AF cohort (n = 93).  
 
Table 3: A comparison of demographic characteristics between a random sample of 
participants with normal diagnoses (n = 93) versus those with cardiologist-confirmed AF 
diagnoses (n = 26). Continuous variables are expressed as a median [interquartile range]. 
Categorical variables are expressed as a number of participants (% total of the group). 
 
 Random Sample with 
Normal Diagnoses (n = 93) 
Participants with 
Cardiologist-confirmed 
AF Diagnoses (n = 26) 
P value(2-
sided) 
Age, years 72 [69; 76] 82 [73; 85] < 0.0001 
Male 36 (38.7) 15 (57.7) 0.116 
Current alcohol drinker  72 (77.4) 16 (61.5) 0.103 
Alcohol, units/week  5.5 [2; 14] (n = 70) 10.0 [2; 14] (n = 16) 0.482 
Current smoker 6 (6.5) 3 (11.5) 0.408 
Height, cm  170.0 [162.5; 175.0] (n = 91) 167.5 [162.5; 177.5] 0.634 
Weight, kg 73.0 [65.1; 81.9] (n = 90) 78.3 [69.7; 97.0] 0.055 
BMI, kg/m2 25.7 [23.1; 28.0] (n = 89) 28.5 [24.2; 33.5] 0.010 
CHA2DS2VASc score  3.0 [2.0; 3.0] (n = 93) 3.0 [3.0; 4.3] 0.002 
Hypertension 38 (40.9) 18 (69.2) 0.010 
Renal disease 16 (17.2) 11 (42.3) 0.007 
Diabetes mellitus 12 (12.9) 8 (30.8) 0.041 
Thyroid disease 8 (8.6) 4 (15.4) 0.293 
Transient ischaemic attack 3 (3.2) 3 (11.5) 0.117 
Ischaemic heart disease 7 (7.5) 3 (11.5) 0.454 
19 
 
Heart failure 0 (0.0) 2 (7.7) 0.046 
Intracranial bleed 1 (1.1) 1 (3.8) 0.391 
Peripheral vascular disease 4 (4.3) 0 (0.0) 0.575 
COPD 8 (8.6) 2 (8.0) 1.000 
 Random Sample with Normal 
Diagnoses (n = 93) 
Participants with Cardiologist-
confirmed AF Diagnoses (n = 26) 
Age, years 72 [69; 76]a 82 [73; 85]a 
Male 36 (38.7) 15 (57.7) 
Current alcohol drinker  72 (77.4) 16 (61.5) 
Alcohol, units/week  5.5 [2; 14] (n = 70) 10.0 [2; 14] (n = 16) 
Current smoker 6 (6.5) 3 (11.5) 
Height, cm  170.0 [162.5; 175.0] (n = 91) 167.5 [162.5; 177.5] 
Weight, kg 73.0 [65.1; 81.9] (n = 90) 78.3 [69.7; 97.0] 
BMI, kg/m2 25.7 [23.1; 28.0]b (n = 89) 28.5 [24.2; 33.5]b 
CHA2DS2VASc score  3.0 [2.0; 3.0]c (n = 93) 3.0 [3.0; 4.3]c 
Hypertension 38 (40.9)d 18 (69.2)d 
Renal disease 16 (17.2)e 11 (42.3)e 
Diabetes mellitus 12 (12.9)f 8 (30.8)f 
Thyroid disease 8 (8.6) 4 (15.4) 
Transient ischaemic attack 3 (3.2) 3 (11.5) 
Ischaemic heart disease 7 (7.5) 3 (11.5) 
Heart failure 0 (0.0)g 2 (7.7)g 
Intracranial bleed 1 (1.1) 1 (3.8) 
Peripheral vascular disease 4 (4.3) 0 (0.0) 
COPD 8 (8.6) 2 (8.0) 
 





The cost-effectiveness of PDAF intervention (see S1 Supporting Information) was estimated 
with a Markov simulation model built using the cost-utility template by Edlin et al. [40],  the 
National Institute for Health and Care Excellence (NICE) costing report for AF [41] and 
methodology adapted from two previous AF screening studies [42,43]. Cost-effectiveness was 
evaluated for the KMD and compared with pulse palpation alone or no screening 
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intervention. The intervention was considered to be cost-effective if the estimated 
incremental cost-effectiveness ratio was under the willingness-to-pay threshold of 
£20,000/quality-adjusted life year (QALY) proposed by NICE [44]. At base case assumptions 
(see S1 Supporting Information), the AF screening strategy was found to be cost-effective in 
71.8% and 64.3% of estimates (100,000 simulations run in each case) for KMD and pulse 
palpation, respectively, compared to no screening intervention. The incremental net benefit 
compared to no screening strategy was £1,903/patient using the KMD and £946/patient using 
pulse palpation. If applied to all patients over 65 years old across England and Wales, with 
50% uptake of screening and AF newly detected as a result of this screening, this would 
represent incremental net benefits of around £120 million using the KMD and £50 million 
using pulse palpation alone. 
 
Follow-up Data and Outcomes 
Following the initial screening and the cardiologist’s interpretation of the SLECG, 87/604 
(14.4%), participants with either possible AF or some other cardiac abnormality were referred 
for a 12-lead (12L) ECG or heart rate check (Fig 3). The median time between screening and 
12LECG was 16.0 [11.0; 24.0] days. One participant declined a 12LECG and GP review, and 4 
participants did not respond to an invitation. Of the remaining participants, 28 (4.6%) had 
normal SR (some identified by GP before 12LECG was done); 22 (3.6%) had a previously 
diagnosed condition and required no further intervention; 4 had newly diagnosed AF (0.7%) 
of whom 3 (0.5%) were initiated on oral anticoagulation and 28 (4.6%) had a newly diagnosed 
non-AF cardiovascular condition. Further details concerning the 28 non-AF conditions 
identified from the SLECG device and reclassifying of patients following 12LECG are shown in 
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Figure 3: Flow chart of follow-up actions and outcomes. 
Abbreviations: 12LECG – 12-lead electrocardiogram; AEB – atrial ectopic beats; AF – atrial 
fibrillation; AVB – first-degree atrioventricular block; BBB – bundle branch block; GP – general 
practitioner; HR – heart rate; LVH – left ventricular hypertrophy; SLECG – single-lead 
electrocardiogram; SR – sinus rhythm; VEB – ventricular ectopic beats. 
 
Participant Experience Questionnaire 
Of the 604 participants screened, 422 (70%) completed a feedback questionnaire. All 
responding participants rated the overall screening experience as either “very good” or 
“good” and 99% agreed that they would be happy to take part in annual repeat AF screening. 
Less than half of all respondents (47%) were aware of AF as a condition before they were 
screened. However, 96% of respondents felt that routine AF screening was either “very 
important” or “important” post-screening. In response to open-ended questions, when asked 
“Was there anything you particularly liked about the service?” there were 272 recorded 
comments. Of these, 75 participants praised the “professional” (14), yet “relaxed”, “friendly” 
and “at ease” nature of the pharmacist-led screening (61), while 24 stated that the service 
improved their access to healthcare by offering an opportunity to obtain a more rapid 
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provisional diagnosis and reassurance about their health status. 94 participants were 
particularly pleased with the “informative” consultation during which they learnt about AF 
and where any information was clearly presented in lay terms, they could understand and 
feel comfortable about and 7 stated that they were particularly impressed with the digital 
technology that was used. A number of participants (32), particularly liked being able to 
contribute to clinical research that had a ”preventative medicine” focus. When participants 
were asked “Was there anything you particularly disliked about the service?” there were only 




This study produced a number of key findings. Firstly, it showed that clinical pharmacists 
assisted by the KMD, were able to detect 24 out of 26 possible AF diagnoses, when compared 
with the over-reading cardiologist. Secondly, participants with confirmed AF had a higher 
incidence of co- or multi-morbidities, including hypertension, renal disease, diabetes and 
heart failure. All ‘known’ and previously ’unknown’ AF participants were at risk of stroke and 
eligible for OACs. Thirdly, screening for AF in the over 65s, combined with another healthcare 
intervention and using the KMD, was cost-effective and financially beneficial, compared with 
no screening at all. Fourthly, the participants felt that screening for AF was important, that 
they were happy for clinical pharmacists to perform the screening and they were very 
impressed by the non-invasive digital technology that was used and the information they 
received from the clinical pharmacist during the appointment. Finally, and arguably the most 
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notable finding, was that using pulse palpation alone resulted in a larger number of false-
positive AF diagnoses compared with the KMD (7.8% vs 2.6%).  
 
Strengths and limitations of the study 
A key strength of this study, was that screening was performed during the influenza 
vaccination season. Since the risk factors associated with AF overlap with those patients 
invited to participate in the seasonal influenza vaccination [45], combining these health 
interventions allowed us to optimise recruitment of a relevant and at-risk population of 
participants with an interest in their own personal well-being and generally in good health at 
the time of screening. In addition, basing the screening within GP practices and combining it 
with another healthcare intervention was cost-effective and convenient for patients and 
ensured that patients received, and had access to: the necessary follow-on care (e.g. 12LECG 
and treatment); and support for an AF or other cardiovascular diagnosis. This is often missing 
from studies performed in other primary care settings, such as community pharmacies. 
However, the space requirement, logistics and staff endorsement of such a screening strategy 
in some GP practices, may be prohibitive. A single time-point strategy can also mean that 
those with PAF are less likely to be detected compared to those with persistent and 
permanent AF.  
Using a SLECG device such as the KMD, which provides a recorded “snap-shot” of a person’s 
heart rhythm was not only beneficial to patients with possible AF, but may also help patients 
that have other previously undetected cardiovascular complications requiring new treatment 
or treatment adjustment, for instance heart failure or sinus bradycardia. However, many of 
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these non-AF cardiovascular diagnoses appeared as an ‘unclassified’ result and required 
manual assessment of the ECG by a cardiac specialist and/or confirmation by a 12LECG.   
A key limitation, although perhaps inevitable of any screening setting, was that the 
intervention did not reach those patients who either by choice or circumstance were unable 
to attend the practice for an influenza vaccination. These included the housebound, those 
with transport issues, patients based in residential and nursing homes or those that simply do 
not engage with healthcare interventions such as the influenza vaccination [46-48]. It is likely 
that many of these patients, who have limited access to healthcare, are perhaps in most need 
of such screening interventions. Indeed, in studies involving care home residents, based in 
the US and Norway, the AF prevalence was found to range from 6.9 to 18.8% [49,50], which 
at the peak is 8 times higher than the prevalence of AF in the general population [51].  
Another limitation of the study was the under-representation of UK ethnic minority groups. 
This study involved predominantly White British participants (97%) and was thus not a true 
representation of the average UK population, which is 80.5% White British [52] (93.7% in Kent 
[53]). Expanding this study into areas where there is a higher representation of ethnic 
minority groups, would be required, to make it nationally representative.  
Measuring the accuracy of the pharmacist to detect AF using the SLECG was limited by the 
protocol design, where the automated algorithm was retained on the KMD. The 
interpretation of the SLECG by the algorithm may have influenced the diagnostic decision 
made by the pharmacist potentially increasing the risk of misclassification bias, and thus the 
level of diagnostic accuracy observed may not be truly representative of their capability. 
Similarly, the accuracy of the pharmacist to pulse palpate may have been compromised by 
their relatively limited training and experience, however, this is perhaps representative of the 
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majority of HCPs and certainly the general population for which pulse palpation is being 
actively promoted. 
 
Comparison with other studies 
The detection of ‘new’ AF in this study was low (0.7%), but comparable to some of the other 
studies screening asymptomatic patients, ≥65 years using the KMD where it varied from 0.5% 
to 1.7% [18,54,55]. This low detection rate may be due in part to the high prevalence (3.6%) 
of ‘known’ AF already in this screened population. The overall prevalence of AF ‘known’ and 
‘new’ in this study was 4.3%, which was consistent with findings from previous studies based 
in GP and outpatient settings (4.4% (95% CI: 4.1 – 4.6%), as reviewed by Lowres et al., (2013) 
[51]. Interestingly, enhanced demographics collected from the medical records of 100 
random participants that had been determined as having normal SR by the cardiologist, 
showed that 7% of these 100 participants had suffered (or were suffering) from known 
AF/PAF, although all were in normal SR at time of screening. This suggests that the true 
prevalence of AF in this population is actually higher than is stated and could potentially be 
as high as 12.3%, as was found in the STROKESTOP study [56].  
Our study showed that those participants with AF were more likely to be older males, with a 
higher BMI and a CHA2DS2-VASc score not lower than 3.0. These data are consistent with 
previous studies [11,12,14]. Our data also highlighted that none of the AF cohort had ‘lone’ 
or idiopathic AF, but all had one or more conventional risk factors for AF of which 
hypertension, renal disease and diabetes mellitus the most common [11,13,14]. These 
findings are consistent with the literature, which has shown ‘lone’ AF to affect as little as 3% 
of the AF population and to occur mainly in those with paroxysmal AF who are under the age 
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of 60 [57], whilst the presence of co- or multi-morbidities is much more common in sufferers 
of AF and reported in a number of studies [12,14,54] and are associated with an increased 
lifetime risk of developing AF [11]. Targeted AF screening of the older population, suffering 
from one or more risk factors, that overlap with the medical indications recommended for 
the influenza vaccination [45], would likely make this a viable screening strategy. 
Importantly, this study directly compared the accuracy of pulse palpation by the clinical 
pharmacist with the use of digital technology (KMD). Few studies have directly compared 
pulse palpation with the newly available digital technology for the detection of AF, despite 
pulse palpation being the recommended method for first-line detection of AF by NICE and 
charities such as the Arrhythmia Alliance [31,58]. Three studies reported that pulse palpation 
had much lower specificity than the newer technology [59-61]. Indirect comparisons reported 
in systematic reviews demonstrated that pulse-palpation in six studies, showed reasonable 
sensitivity (0.92 [0.85 - 0.96]) as a technique, however, specificity (0.82 [0.76 - 0.88]) was 
much lower compared to other methods [29]. In this study, sensitivity and specificity of pulse 
palpation by the clinical pharmacist was much lower than using the KMD. The KMD had 
superior specificity in the detection of AF, with over 5%, fewer false positive results, than 
pulse palpation. The operating capabilities of the KMD and its algorithm in this study were 
also found to be comparable to previous studies in similar or different settings, where 
sensitivity and specificity varied between 55 – 100% and 82 – 99% respectively [42,62-65]. 
Reliance on pulse palpation alone would have resulted in a higher number of false positives 
and false negatives. Interestingly, few studies fail to quote the % of false discoveries, i.e. the 
number of AF diagnoses from all the potential AF diagnoses that were incorrect. This is 
perhaps because these numbers appear to be alarmingly high. In this study, pulse palpation 
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had a false discovery rate of 69%. In other words, using pulse palpation in isolation, would 
have resulted in 65 out of 604 participants, being informed that they potentially had AF, but 
45 of these would have been incorrect. The KMD had a false discovery rate of 38.5% (15 out 
of 39). This is not a negligible amount, but considerably better than for pulse palpation. The 
issue of using pulse palpation as a first step in the detection of AF is that an irregular pulse is 
not just an indicator of AF, but also of many other conditions [29] and, therefore, 70 - 87% of 
all pulse irregularities will not be AF [66]. Consequently, mass screening using pulse-palpation 
will lead to a high number of false-positives and to a lesser extent false-negatives when used 
solely as a screening test for AF [29,59,60]. For many patients, being told that they possibly 
had AF would likely cause undue worry and concern if not dealt with correctly by those doing 
the screening and would be particularly problematic if the patient was independently 
screening themselves.  
This study also demonstrated that screening for AF in primary care during the influenza 
vaccination season, using a KMD device and clinical pharmacist was likely to be cost-effective, 
in nearly 72% of cases, at a threshold of £20,000 per QALY, compared with no screening at 
all. These health economic outcomes are aligned with health economic evaluations in other 
studies using similar conditions [42,43,67]. 
Interestingly, AF screening results presented here revealed that only 7 out 18 patients with 
previously diagnosed AF were fully aware of their condition. In line with these findings, less 
than 50% of respondents to questionnaires were aware of AF and related health risks prior to 
being screened. While the phenomenon of poor AF awareness amongst general public is not 
new [68], it highlights the value of healthcare education provided by qualified HCPs, such as 
pharmacists, undertaking the screening. In turn, respondents to the questionnaire 
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appreciated the informative and user-friendly consultation with the pharmacist, which 
improved their access to healthcare and provided immediate reassurance. As reported by 
previous AF screening studies in primary care [17,69,70], patients were also fascinated by 
SLECG technology, showcasing the potential of using KMD as a multi-purpose screening and 
educational tool by future AF screening initiatives.  
 
Conclusion and policy implications  
Future screening initiatives will require the involvement of HCPs based in general practices, 
in particular, clinical pharmacists. Clinical pharmacists can mitigate stress that may occur due 
to false discoveries; have the potential to treat and manage both the condition and the 
associated risk factors linked to other coexisting diseases and can educate the population 
about the disease. Their participation can assure the longevity of any future AF screening 
programmes. This study highlights the need for a change in guidelines to move from less 
reliable and less sensitive practices such as pulse palpation as the first-line of AF detection to 
the adoption of specifically purposed modern technology.  
 
Future direction 
The present study has demonstrated that coupling an AF screening initiative with the 
influenza vaccination programme is feasible, cost-effective and has a high degree of 
acceptability to patients.  However, key questions remain relating to whether this model 
could be upscaled and delivered by pharmacists or other HCPs, in all GP practices and without 
the 'insurance' of a cardiologist screening all ECGs. Acceptability by patients has been 
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reported here, however, the key barriers perceived by policymakers which have prevented 
the adoption of a national programme are yet to be explored.  Furthermore, the service is not 
equitable, as whilst it was freely available to all, those who are more proactive about their 
health, are more likely to participate. Further research therefore, needs to focus on more 
inclusive strategies to ensure that routine AF screening is available to those from differing 
social, economic, and cultural backgrounds. 
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